Ace2 fusion proteins and uses thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsNianshuang WANG, Yang SHEN, Alina BAUM, Christos KYRATSOUS, Chia-Yang LIN
Life of this patent
Estimating the term…
Abstract
The present disclosure provides ACE2 fusion proteins, comprising multimerization moieties linked to ACE2 moieties, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the ACE2 fusion proteins, pharmaceutical compositions comprising of the ACE2 fusion proteins, and methods of use of the ACE2 fusion proteins to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Claims38
An ACE2 fusion protein comprising one or more polypeptide chains having the formula:
- (a) [A1] represents an ACE2 moiety;
- (b) [L1] represents a linker;
- (c) [MM1] represents a multimerization moiety;
- (d) [L2] represents a linker;
- (e) [MM2] represents a multimerization moiety;
- (f) [L3] represents a linker;
- (g) [A2] represents an ACE2 moiety;
- (h) [L4] represents a linker;
- and
- (i) [MM3] represents a multimerization moiety,
- and wherein:
- (i) each of [L1], [L2], [L3] and [L4] may be absent;
- (ii) one or both of [MM1] and [MM3] may be absent;
- (iii) one but not both of [A1] and [A2] may be absent;
- and
- (iv) [MM2] is present and is an IgG1 PVA Fc domain.
-19. (canceled)
-28. (canceled)
An ACE2 fusion protein comprising one or more polypeptide chains having the formula:
- wherein:
- (a) [A1] represents an ACE2 moiety;
- (b) [L1] represents a linker;
- (c) [MM1] represents a multimerization moiety;
- (d) [L2] represents a linker;
- (e) [MM2] represents a multimerization moiety;
- (f) [L3] represents a linker;
- (g) [A2] represents an ACE2 moiety;
- (h) [L4] represents a linker;
- and
- (i) [MM3] represents a multimerization moiety,
- and wherein:
- (i) each of [L1], [L2], [L3] and [L4] may be absent;
- (ii) one or two but not all three of [MM1], [MM2] and [MM3] may be absent;
- (iii) one but not both of [A1] and [A2] may be absent;
- and
- (iv) at least one of [A1] and [A2] is present and comprises the amino acid substitutions T27Y, L79T, and N330Y.
Dependencies are inferred from the claim text.